The contribution of a 2-amino group on receptor tyrosine kinase inhibition and antiangiogenic activity in 4-anilinosubstituted pyrrolo[2,3-d]pyrimidines.
Comparison between a series of pyrrolo[2,3-d]pyrimidines with and without the 2-amino group is presented in order to determine the validity of our hypothesis that inclusion of this group improves potency against receptor tyrosine kinases (RTK). The 2-amino analogs were better against epidermal growth factor receptor (EGFR) and platelet derived growth factor-beta (PDGFR-beta) in whole cell inhibition assays and in the A431 cytotoxicity assay compared to the 2-desamino analogs. However, the 2-desamino analogs were more potent inhibitors against vascular endothelial growth factor-2 (VEGFR-2) than the corresponding 2-amino compounds. In addition, none of the 2-desamino compounds exhibited better anti-angiogenic activity in the chorioallantoic membrane (CAM) assay as compared to the standard and were only micromolar inhibitors. This study validates our original hypothesis that the inclusion of a 2-amino group in pyrrolo[2,3-d]pyrimidines improves multiple RTK inhibition and antiangiogenic activity.
Gangjee
Aleem
A
Division of Medicinal Chemistry, Graduate School of Pharmaceutical Sciences, Duquesne University, Pittsburgh, PA 15282, USA. gangjee@duq.edu
Namjoshi
Ojas A
OA
Ihnat
Michael A
MA
Buchanan
Aaron
A
D020533:Angiogenesis Inhibitors / Q000138:chemical synthesis / Q000737:chemistry* / Q000633:toxicity; D020134:Catalytic Domain; D045744:Cell Line, Tumor; D003198:Computer Simulation; D066246:ErbB Receptors / Q000037:antagonists & inhibitors / Q000378:metabolism; D006801:Humans; D047428:Protein Kinase Inhibitors / Q000138:chemical synthesis / Q000737:chemistry* / Q000633:toxicity; D011743:Pyrimidines / Q000138:chemical synthesis / Q000737:chemistry* / Q000633:toxicity; D020794:Receptor Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors* / Q000378:metabolism; D013329:Structure-Activity Relationship; D040301:Vascular Endothelial Growth Factor Receptor-2 / Q000037:antagonists & inhibitors / Q000378:metabolism
D020533:Angiogenesis Inhibitors; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D066246:ErbB Receptors; D020794:Receptor Protein-Tyrosine Kinases; D040301:Vascular Endothelial Growth Factor Receptor-2
Mol Cancer Res. 2007 Mar;5(3):203-20
17374728
Mol Cancer Ther. 2006 May;5(5):1280-9
16731761
Semin Oncol. 2002 Dec;29(6 Suppl 16):10-4
12516033
Nat Rev Cancer. 2004 Dec;4(12):956-65
15573117
Semin Oncol. 2006 Aug;33(4):407-20
16890796
Bioorg Med Chem. 2003 Nov 17;11(23):5155-70
14604679
Cancer Res. 2000 Feb 15;60(4):970-5
10706112
Int J Cancer. 1990 Mar 15;45(3):416-22
2307530
Bioorg Med Chem. 2008 May 15;16(10):5514-28
18467105
Expert Opin Investig Drugs. 2003 Jan;12(1):51-64
12517254
Cell Prolif. 1999 Apr-Jun;32(2-3):131-40
10535359
Nat Med. 2003 Jun;9(6):669-76
12778165
Chem Pharm Bull (Tokyo). 1995 May;43(5):797-817
7553967
Chem Pharm Bull (Tokyo). 1995 May;43(5):788-96
7553966
Chem Rev. 2001 Aug;101(8):2541-72
11749388
Cancer Res. 1999 Jan 1;59(1):99-106
9892193
J Med Chem. 1999 Dec 30;42(26):5464-74
10639288
Biol Pharm Bull. 2002 May;25(5):597-604
12033499
Eur J Cancer. 2006 Jul;42(10):1351-6
16740386
Semin Oncol. 2002 Dec;29(6 Suppl 16):3-9
12516032
Annu Rev Med. 2006;57:1-18
16409133
Hematol Oncol Clin North Am. 2004 Oct;18(5):1007-21, viii
15474332
Chem Biol. 1999 Feb;6(2):71-83
10021420